China Universal Asset Management Co. Ltd. Buys 3,732 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

China Universal Asset Management Co. Ltd. lifted its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 64.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,564 shares of the company’s stock after acquiring an additional 3,732 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Mineralys Therapeutics were worth $116,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of Mineralys Therapeutics during the 3rd quarter worth $110,000. Nantahala Capital Management LLC increased its stake in shares of Mineralys Therapeutics by 60.1% in the second quarter. Nantahala Capital Management LLC now owns 532,506 shares of the company’s stock worth $6,230,000 after purchasing an additional 200,000 shares during the period. Driehaus Capital Management LLC lifted its position in shares of Mineralys Therapeutics by 40.4% during the 2nd quarter. Driehaus Capital Management LLC now owns 257,371 shares of the company’s stock worth $3,011,000 after purchasing an additional 74,074 shares during the last quarter. Lion Point Capital LP lifted its holdings in shares of Mineralys Therapeutics by 31.7% during the second quarter. Lion Point Capital LP now owns 79,000 shares of the company’s stock worth $924,000 after buying an additional 19,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Mineralys Therapeutics in the second quarter valued at approximately $145,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Stock Down 2.9 %

Mineralys Therapeutics stock opened at $13.38 on Friday. The business has a 50 day moving average price of $12.69 and a two-hundred day moving average price of $12.50. Mineralys Therapeutics, Inc. has a 12 month low of $5.85 and a 12 month high of $16.91. The stock has a market cap of $664.30 million, a price-to-earnings ratio of -6.11 and a beta of 1.93.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Tuesday, August 13th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). During the same quarter last year, the business posted ($0.31) earnings per share. On average, analysts expect that Mineralys Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research report on Thursday.

Insider Transactions at Mineralys Therapeutics

In related news, CFO Adam Scott Levy sold 10,757 shares of the company’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the sale, the chief financial officer now owns 236,854 shares of the company’s stock, valued at $3,214,108.78. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $13.57, for a total transaction of $145,972.49. Following the completion of the transaction, the chief financial officer now owns 236,854 shares in the company, valued at $3,214,108.78. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jon Congleton sold 15,271 shares of the stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $13.52, for a total transaction of $206,463.92. Following the sale, the chief executive officer now owns 895,941 shares of the company’s stock, valued at $12,113,122.32. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 33.24% of the stock is owned by insiders.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.